Managing Diabetes & CVD: Is epigenetics a new way forward?
EBAC-accredited E-learningOnline-CME - This course consists of 3 lectures
This CME accredited course consists of 3 separate lectures. View all 3 lectures and earn 1 CME credit. The content of this course is based on a CME symposium held on August 27, 2017 at the ESC congress in Barcelona.
This course consists of the following lectures:
- Managing high risk diabetes patients with cardiovascular disease: What works, and what else can we do? - by Kausik Ray, MD - Imperial College London, United Kingdom
- Promise of epigenetic modulation as a target in atherosclerotic patients - by Erik Stroes, MD; Academic Medical Centre, Amsterdam, The Netherlands
- Insights from the first trials in epigenetics in human: What is the way forward? - by Stephen Nicholls, MD; Adelaide, Australia
Educational objectives of this course are to:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit
This is available as accredited online CME for members. Click the button below to enroll:Enroll